Use of cholecystokinin-octapeptide for the prevention of parenteral nutrition-associated cholestasis

What Was Tested

The paper reports a study of Cholecystokinin (CCK) and Sincalide, published as a randomized controlled trial.

Who Took Part

Neonates at risk for the development of PNAC included very low birth weight neonates and those with major surgical conditions involving the gastrointestinal tract.

Eligible infants were all <30 days of age.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

The participants were allocated by chance, so the Cholecystokinin (CCK) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Cholecystokinin (CCK), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Cholecystokinin (CCK) could be set against what happens without it.

Running at several centres spread the Cholecystokinin (CCK) study over different clinics and patient groups.

The methods mention a period of 2 weeks.

This was a multicenter, double-blind, randomized, controlled trial conducted between 1996 and 2001.

Patients were enrolled within 2 weeks after birth or within 7 days after surgery.

What Was Measured

Topics PubMed links to this paper include Bilirubin, Cholestasis, Gallbladder, Infant, Premature, Infant, Premature, Diseases, Infant, Very Low Birth Weight and Parenteral Nutrition, Total.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Cholecystokinin (CCK) and Sincalide over 2 weeks.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2005 (Pediatrics), a journal based in United States.

More context: the Cholecystokinin (CCK) compound page and the Sincalide compound page, all human trials.